ASIRI SURGICAL HOSPITAL PLC
INTERIM FINANCIAL STATEMENT FOR THE YEAR ENDED
31 March 2026

Asiri Surgical Hospital PLC

STATEMENT OF PROFIT OR LOSS

For the Year Ended 31 March

	Group		Company	
	2026	2025	2026	2025
	Rs. Un-audited	Rs. Audited	Rs. Un-audited	Rs. Audited
Revenue	7,721,879,459	7,182,101,294	7,014,759,645	6,448,457,858
Cost of Services	(4,373,891,158)	(4,180,926,870)	(4,090,672,379)	(3,876,272,373)
Gross Profit	3,347,988,301	3,001,174,424	2,924,087,266	2,572,185,485
Other Income	76,576,048	47,145,816	126,495,094	93,170,549
Administrative Expenses	(1,916,833,447)	(2,131,621,912)	(1,877,743,418)	(2,066,844,741)
Selling and Distribution Costs	(200,297,053)	(244,540,075)	(172,295,239)	(216,207,725)
Finance Cost	(329,985,467)	(341,042,132)	(329,790,719)	(378,335,646)
Finance Income	642,311,699	562,068,796	589,735,273	559,758,994
Change in Fair Value of Investment Property	-	-	-	58,600,000
Profit Before Tax	1,619,760,080	893,184,917	1,260,488,256	622,326,916
Tax Expense	(643,290,965)	(519,456,799)	(538,843,716)	(428,830,575)
Profit for the Year	976,469,115	373,728,118	721,644,541	193,496,340
Attributable to:				
Equity holders of the parent	822,891,332	265,665,080		
Non-controlling interest	153,577,783	108,063,038		
Earnings Per Share - Basic	1.56	0.50	1.37	0.37
Dividend Per Share	0.00	0.30	0.00	0.30

Asiri Surgical Hospital PLC

STATEMENT OF COMPREHENSIVE INCOME

For the Year Ended 31 March

	Group		Company	
	2026	2025	2026	2025
	Rs. Un-audited	Rs. Audited	Rs. Un-audited	Rs. Audited
Profit for the Year	976,469,115	373,728,118	721,644,541	193,496,340
Other Comprehensive Income/(Loss)				
Other Comprehensive Income/(Loss) not to be reclassified to profit or loss in subsequent periods (net of tax) :				
Revaluation surplus on building	-	243,412,726	-	184,812,726
Actuarial gain/(loss) on retirement benefit liability	-	(9,549,734)	-	(9,545,833)
Net (Gain/Loss) an investment Subsidiary at FVOCI	-	-	-	407,378,229
Net (Gain/Loss) an Equity instrument Subsidiary at FVOCI	-	11,146,224	-	11,146,224
	-	245,009,217	-	593,791,347
Deferred Tax on Other Comprehensive Income	-	(70,161,238)	-	(174,793,537)
Net Other Comprehensive Income that will not to be reclassified to profit or loss in subsequent periods (net of tax)	-	174,847,979	-	418,997,810
Other Comprehensive Income for the year, net of tax	-	174,847,979	-	418,997,810
Total Comprehensive Income for the year, net of tax	976,469,115	548,576,098	721,644,541	612,494,150
Total Comprehensive Income Attributable to:				
Equity holders of the parent company	822,891,332	440,515,595		
Non-controlling interest	153,577,783	108,060,503		

Asiri Surgical Hospital PLC

STATEMENT OF PROFIT OR LOSS

For the Three Months Ended 31 March

	Group		Company	
	2026	**2025**	**2026**	**2025**
	Rs. **Un-audited**	**Rs.** **Un-audited**	**Rs.** **Un-audited**	**Rs.** **Un-audited**
Revenue	1,871,852,331	1,831,071,940	1,744,051,315	1,660,500,223
Cost of Services	(1,077,084,414)	(1,047,148,787)	(1,027,079,216)	(972,625,819)
Gross Profit	794,767,917	783,923,153	716,972,099	687,874,404
Other Income	17,172,051	405,238	29,332,742	12,134,023
Administrative Expenses	(481,636,401)	(381,465,471)	(472,521,830)	(363,624,421)
Selling and Distribution Costs	(50,056,636)	(46,982,558)	(44,732,379)	(36,056,345)
Finance Cost	(118,426,906)	(77,261,049)	(80,906,970)	(87,662,298)
Finance Income	253,429,330	99,866,689	201,552,003	99,529,250
Profit Before Tax	415,249,356	378,486,002	349,695,664	312,194,613
Tax Expense	(163,577,728)	(165,109,934)	(148,028,525)	(143,808,042)
Profit for the Period	251,671,628	213,376,068	201,667,139	168,386,571
Attributable to:				
Equity holders of the parent	201,484,670	189,335,083		
Non-controlling interest	50,186,958	24,040,983		
Earnings Per Share - Basic	0.38	0.29	0.38	0.32
Dividend Per Share	0.00	0.00	0.00	0.00

STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended 31 March

	Group		Company	
	2026	**2025**	**2026**	**2025**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Profit for the Period	251,671,628	213,376,067	201,667,139	168,386,572
Other Comprehensive Income/(Loss)				
Other Comprehensive Income/(Loss) not to be reclassified to profit or loss in subsequent periods (net of tax) :				
Revaluation surplus on building	-	-	-	-
Actuarial gain/(loss) on retirement benefit liability	-	-	-	-
Share of joint venture other comprehensive income (net of income tax)	-	-	-	-
	-	213,376,067	-	168,386,572
Deferred Tax on Other Comprehensive Income	-	-	-	-
Net Other Comprehensive Income not to be reclassified to profit or loss in subsequent periods (net of tax)	-	213,376,067	-	168,386,572
Other Comprehensive Income/(Loss) for the period, net of tax	-	213,376,067	-	168,386,572
Total Comprehensive Income for the period, net of tax	251,671,628	213,376,067	201,667,139	168,386,572
Attributable to:				
Equity holders of the parent	169,808,704	123,288,005		
Non-controlling interest	81,862,924	90,088,063		

STATEMENT OF FINANCIAL POSITION

	Group		Company	
	As at 31-Mar-26 Rs. Un-audited	As at 31-Mar-25 Rs. Audited	As at 31-Mar-26 Rs. Un-audited	As at 31-Mar-25 Rs. Audited
ASSETS				
Non-current Assets				
Property, Plant and Equipment	5,640,171,546	5,524,084,997	5,257,879,042	5,147,839,808
Right-of-use Asset	16,833,650	17,067,993	16,833,650	17,067,993
Investment property	-	-	226,400,000	226,400,000
0	-	-	1,881,194,730	1,881,194,729
Loans Granted to Related Parties	1,979,529,017	1,979,529,017	1,979,529,017	1,979,529,017
Non Current Assets	-	25,982,000	-	25,982,000
	7,636,534,213	**7,546,664,008**	**9,361,836,438**	**9,278,013,548**
Current Assets				
Inventories	210,617,251	138,362,803	206,279,550	135,318,841
Trade and Other Receivables	1,265,723,504	1,315,529,766	1,230,262,662	1,170,845,045
Other Current Assets	2,459,023,308	1,365,150,335	2,459,023,308	1,365,150,335
Loans Granted to Related Parties	4,100,477,835	3,736,839,663	4,100,477,835	3,736,839,663
Cash and Cash Equivalents	649,097,086	336,399,603	151,211,601	57,999,515
	8,684,938,984	**6,892,282,171**	**8,147,254,956**	**6,466,153,398**
Total Assets	**16,321,473,197**	**14,438,946,178**	**17,509,091,395**	**15,744,166,946**
EQUITY AND LIABILITIES				
Stated Capital	1,393,327,565	1,393,327,565	1,393,327,565	1,393,327,565
Other Components of Equity	2,633,391,827	2,633,391,827	3,905,525,939	3,905,525,939
Retained Earnings	3,269,755,844	2,446,864,512	2,809,396,097	2,087,751,556
Share Holders' Fund	**7,296,475,236**	**6,473,583,903**	**8,108,249,601**	**7,386,605,060**
Non-Controlling Interests	572,338,085	418,760,302	-	-
Total Equity	**7,868,813,321**	**6,892,344,205**	**8,108,249,601**	**7,386,605,060**
Non-current Liabilities				
Lease Liability	25,586,480	25,586,483	25,586,480	25,586,483
Interest Bearing Loans and Borrowings	183,494,504	557,668,563	183,494,504	557,668,563
Employee Benefit Liability	208,258,786	184,869,607	200,765,984	179,009,334
Deferred Tax Liability	1,249,016,508	1,259,268,153	1,771,780,070	1,771,780,071
	1,666,356,278	**2,027,392,805**	**2,181,627,038**	**2,534,044,451**
Current Liabilities				
Trade and Other Payables	3,229,810,208	2,363,782,158	3,126,715,127	2,265,491,425
Dividend Payable	14,309,425	14,401,722	14,309,425	14,401,722
Lease Liability	5,420,408	5,420,408	5,420,408	5,420,408
Interest Bearing Loans and Borrowings	1,659,029,611	1,842,659,723	2,255,729,611	2,314,359,723
Income Tax Payable	1,024,354,631	818,195,302	963,660,867	749,094,300
Bank Overdraft	853,379,316	474,749,856	853,379,316	474,749,856
	6,786,303,598	**5,519,209,168**	**7,219,214,755**	**5,823,517,434**
Total Equity and Liabilities	**16,321,473,197**	**14,438,946,178**	**17,509,091,394**	**15,744,166,945**
Net Assets Per Share	14.89	12.25	15.34	13.98

Sgd.
Mr. S.L.R Piyal
Director Finance

Sgd.
Mr. Ashok Pathirage
Chairman / Managing Director

Sgd.
Mr. Haresh Kaimal
Director

30th April 2026
Colombo

STATEMENT OF CHANGES IN EQUITY

For the Year Ended 31 March

Group

	Attributable to equity holders of parent						
	Stated Capital Rs.	FV Reserves of Financial Assets at FVOCI Rs.	Revaluation Reserves Rs.	Retained Earnings Rs.	Total Rs.	Non - Controlling Interest Rs.	Total Equity Rs.
Balance as at 01 April 2024	1,393,327,565	-	2,463,002,918	2,573,018,652	6,191,605,575	310,699,799	6,502,305,372
Profit for the Year	-	-	-	265,665,080	265,665,080	108,063,038	373,728,118
Other comprehensive Income	-	11,146,224	170,388,908	(6,684,618)	174,850,514	(2,536)	174,847,978
Total Comprehensive Income	-	11,146,224	170,388,908	258,980,462	440,515,594	108,060,503	548,576,097
Interim Dividend Paid - Ordinary Shares	-	-	-	(158,537,264)	(158,537,264)	-	(158,537,264)
Transfer to Retained Earnings	-	226,597,338	-	(226,597,338)	-	-	-
Balance as at 31 March 2025	**1,393,327,565**	-	**2,633,391,827**	**2,446,864,512**	**6,473,583,904**	**418,760,302**	**6,892,344,205**
Balance as at 01 April 2025	1,393,327,565	-	2,633,391,827	2,446,864,512	6,473,583,904	418,760,302	6,892,344,206
Profit for the Period	-	-	-	822,891,332	822,891,332	153,577,783	976,469,115
Other comprehensive Income	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	822,891,332	822,891,332	153,577,783	976,469,115
Balance as at 31 March 2026	**1,393,327,565**	-	**2,633,391,827**	**3,269,755,844**	**7,296,475,237**	**572,338,085**	**7,868,813,321**

Company

	Stated Capital Rs.	FV Reserves of Financial Assets at FVOCI Rs.	Revaluation Reserves Rs.	Retained Earnings Rs.	Total Equity Rs.
Balance as at 01 April 2024	1,393,327,565	770,267,916	2,482,980,793	2,286,071,900	6,932,648,174
Profit for the Year	-	-	-	193,496,340	193,496,340
Other comprehensive Income	-	296,310,984	129,368,908	(6,682,083)	418,997,809
Total Comprehensive Income	-	296,310,984	129,368,908	186,814,257	612,494,149
Interim Dividend Paid - Ordinary Shares	-	-	-	(158,537,264)	(158,537,264)
Transfer to Retained Earnings	-	226,597,338	-	(226,597,338)	-
Balance as at 31 March 2025	**1,393,327,565**	**1,293,176,237**	**2,612,349,702**	**2,087,751,556**	**7,386,605,060**
Balance as at 01 April 2025	1,393,327,565	1,293,176,237	2,612,349,702	2,087,751,555	7,386,605,060
Profit for the Period	-	-	-	721,644,541	721,644,541
Other comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	721,644,541	721,644,541
Balance as at 31 March 2026	**1,393,327,565**	**1,293,176,237**	**2,612,349,702**	**2,809,396,097**	**8,108,249,601**

STATEMENT OF CASH FLOWS

For the Year Ended 31 March

	Group		Company	
	2026	2025	2026	2025
Cash Flows From Operating Activities	Rs.	Rs.	Rs.	Rs.
Profit Before Income Tax Expense	1,619,760,080	893,184,917	1,260,488,256	622,326,916
Adjustments for				
Amortization of Right of use Asset	234,343	234,343	234,343	234,343
Depreciation	401,757,192	389,790,735	359,849,522	345,269,354
Loss on Sale of Property, Plant and Equipment	234,343	8,936	1,910,314	8,936
Finance Income	(642,311,699)	(562,068,796)	(589,735,273)	(545,316,646)
Finance Expense	329,985,467	341,042,132	329,790,719	378,335,646
Unrealized Foreign Currency Exchange Gain	(1,148,850)	(5,462,244)	(1,148,850)	(5,462,244)
Provision for Retirement Obligation Plan	45,476,996	37,746,242	43,826,996	36,246,064
Provision for Bad Debts	1,571,678	62,066,491	1,571,678	62,066,491
Inventory Write off	-	5,857,605	-	5,857,605
Rou Liabilty reassement Loss	-	29,389,537	-	29,389,537
Impairment of loans & Other receivables	-	313,246,762	-	313,246,762
Scrip dividends received	-	(14,442,348)	-	(14,442,348)
Change in Fair Value of Investment Property	-	-	-	(58,600,000)
Operating Profit Before Working Capital Changes	1,755,559,551	1,490,594,310	1,406,787,706	1,169,160,414
Changes in Working Capital				
(Increase)/Decrease in Inventories	(72,254,448)	68,480,061	(70,960,710)	67,274,988
(Increase)/Decrease in Trade and Other Receivables	(313,831,910)	(682,453,556)	(423,055,788)	(565,519,281)
(Increase)/Decrease in Other Current Assets	(1,093,872,974)	(1,365,150,335)	(1,093,872,974)	(1,365,150,335)
Increase/(Decrease) in Trade and Other Payables	866,028,050	1,016,805,122	861,223,702	960,405,847
	(613,931,282)	(962,318,707)	(726,665,770)	(902,988,781)
Cash Generated From Operations	1,141,628,269	528,275,602	680,121,936	266,171,633
Income Tax paid	(446,319,719)	(299,798,638)	(305,464,801)	(218,655,959)
Finance Costs paid	(306,816,270)	(326,862,484)	(324,370,313)	(364,155,998)
Defined Benefit Plan Costs paid	(21,774,120)	(24,270,226)	(21,756,650)	(24,270,226)
Net Cash Flows From Operating Activities	366,718,159	(122,655,745)	28,530,172	(340,910,549)
Cash Flows From/(Used in) Investing Activities				
Acquisition of Property, Plant and Equipment	(520,836,248)	(312,411,077)	(472,881,261)	(306,031,117)
Proceeds from Sale of Shares	-	270,388,572	-	270,388,572
Proceeds from Sale of Property, Plant & Equipment	1,910,314	-	1,910,314	-
Loans Granted to Related Parties	-	(17,000,000)	-	(17,000,000)
Finance income received	642,311,699	534,892,378	589,735,273	532,582,576
Loans Received from Related Parties	-	-	125,000,000	150,000,000
Net Cash Flows From Investing Activities	123,385,765	475,869,874	243,764,326	629,940,032
Cash Flows from /(Used in) Financing Activities				
Proceeds From Interest Bearing Loans and Borrowings	-	198,727,233		198,727,233
Repayment of Lease Liability	-	(5,420,408)	-	(5,420,408)
Repayment of Interest Bearing Loans and Borrowings	(557,804,171)	(571,544,820)	(557,804,171)	(554,044,820)
Dividend Paid	92,298	(50,785,633)	92,298	(50,785,633)
Net Cash Flows from Decrease Used in Financing Activities	(557,711,872)	(429,023,627)	(557,711,872)	(411,523,627)
Net Increase in Cash and Cash Equivalents	(65,931,977)	(75,809,501)	(285,417,374)	(122,494,145)
Cash and Cash Equivalents at the beginning of the year	(138,350,253)	(62,540,752)	(416,750,341)	(294,256,196)
Cash and Cash Equivalents at the end of the year	(204,282,231)	(138,350,253)	(702,167,716)	(416,750,341)
Cash & Cash Equivalents				
Cash and Bank Balances	649,097,086	336,399,603	151,211,601	57,999,514
Bank Overdrafts	(853,379,316)	(474,749,856)	(853,379,316)	(474,749,856)
	(204,282,230)	(138,350,253)	(702,167,715)	(416,750,342)

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Year Ended 31 March 2026

1. Corporate Information

1.1 General

Asiri Surgical Hospital PLC ("Company") is a public limited liability Company, incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. The registered office and principal place of business is located at No. 21, Kirimandala Mawatha, Colombo 5.

1.2 Date of Authorisation for Issue

The Interim Condensed Financial Statements of the Group and the Company for the year ended 31 March 2026 were authorised for issue by the Board of Directors on 30 April 2026.

2. Basis of Preparation

The interim condensed financial statements have been prepared in accordance with Sri Lanka Accounting Standard - LKAS 34 Interim Financial Reporting. These interim condensed financial statements should be read in conjunction with the annual financial statements for the year ended 31 March 2025. These financial statements provide the information as required in terms of Rule 7.4 of the Colombo Stock Exchange. The presentation and classification of the financial statements of the previous period have been amended, where relevant, for better presentation and to be comparable with those of the current period.

3. Accounting Policies

The same accounting policies and methods of computation as stated in the annual financial statements for the year ended 31 March 2025 are followed in the preparation of these Interim Condensed Financial Statements.

4. Other Information

4.1 Loans Granted to Related Parties

This includes loans granted to Asiri Hospital Holdings PLC, The Central Hospital Limited, Asiri Hospital Matara Pvt Ltd, Softlogic Retail Pvt Ltd, Asiri Central Hospital Limited, Softlogic Communications (Pvt) Ltd, Softlogic Brands (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

4.2 Contingent Liabilities

A dispute has arisen with the Department of Inland Revenue with regard to the applicability of the income tax exemption for the years of assessment 2005/06 to 2014/15, in terms of the agreement entered between Asiri Surgical Hospital PLC and the Board of Investment of Sri Lanka (BOI) in 2000. With respect to the same we have received written notifications from the Tax Appeal Commission so far for the years of assessments from 2005/06 to 2013/14 and the company is assessing the provisioning requirement based on the applicable tax laws during that period. The Company has filed appeals against these assessments in the Court of Appeal and the cases are on going

We also have filed an appeal in the Supreme Court(vide Supreme Court Special Leave To APPEAL APP: SC/SPL/LA 69/2026] against the Judgment of the Court of Appeal dated 19th January 2026 relating to the Writ application (CA (Writ) 386/ 2016 which was filed by the Company to prevent seizure of bank accounts of the Company as part of IRD's recovery actions .

Since there are litigations, in accordance with Paragraph 92 of LKAS 37, we are unable to provide further information on this and associated risks, in order not to impair the outcome and/or prejudice the Company's position in this matter.

Other than above, there are no significant changes in the nature of the contingent liabilities and contingent assets which were disclosed in the Annual Report for the year ended 31 March 2025.

4.3 Capital Expenditure Commitments

There were no material commitments outstanding as at 31 March for future capital expenditure.

4.4 Comparative Information

Where necessary comparative figures have been reclassified to conform with the current year's presentation.

4.5 Share Capital

Issued and fully paid number of Ordinary Shares as at 31 March 2026 stands at 528,457,545.

5. Event after the balance sheet

No other events have occurred since the date of the Statement of Financial Position that necessitates adjustments to/or disclosures in the Provisional Accounts.

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Year Ended 31 March 2026

6. Segment Information

The Senior Management Committee acts as the Chief Operating Decision Maker (CODM) and reviews the operating results of the Group's business units separately to support decisions on resource allocation and performance evaluation. Segment performance is assessed based on revenue and other income generated, measured on a basis consistent with the amounts reported in the Consolidated Financial Statements.

Based on the information presented to the CODM for these purposes, the Group has identified its reportable segments accordingly for the interim period.

- Pre Care which include OPD revenue, channeling revenue and OPD lab investigation services
- Post Care which include all IPD revenue including inpatient drugs and lab investigation
- Pharmaceutical which includes Pharmacy revenue

Segment	Group		Company	
	2026	2025	2026	2025
	Rs.	Rs.	Rs.	Rs.
Pre Care	3,019,018,546	2,744,279,629	2,311,898,732	2,010,636,193
Post Care	4,522,382,503	4,187,956,197	4,522,382,503	4,187,956,197
Pharmaceutical	180,478,410	249,865,468	180,478,410	249,865,468
	7,721,879,459	7,182,101,294	7,014,759,645	6,448,457,858

INVESTOR INFORMATION

Market Value of Shares

The market value of an ordinary share of Asiri Surgical Hospital PLC is as follows:

	Quarter ended 31-Mar-26	Quarter ended 31-Mar-25
- Highest Market Price – Rs.	17.80	13.20
- Lowest Market Price – Rs.	13.50	10.50
- Last Traded Price – Rs.	15.40	11.50

No of Shares Representing Stated Capital

	As at 31-Mar-26	As at 31-Mar-25
No of Ordinary Shares	528,457,545	528,457,545

* Earnings & net assets per share are based on 528,457,545 shares in issue as at 31 March 2026.

Statement of Shareholding of Directors

Name of Director	As at 31-Mar-26	As at 31-Mar-25
Mr. A. K. Pathirage	-	-
Mr. H. K. Kaimal	-	-
Mr. R. Selvaskadan	-	-
Mr. G.W.D.H.U. Gunawardena	-	-
Mr. Saar Shapira	-	-
Mr. I.M. Furkan	-	-
Mr. G.D.K.L. De Silva	-	-

Major Shareholdings

Twenty Largest Shareholders	31-Mar-26 No. of Shares	%	31-Mar-25 No. of Shares	%
Asiri Hospital Holdings PLC	422,555,413	79.96	422,555,413	79.96
Mr. D.K. Subasinghe / Mrs. S.N. Subasinghe	39,014,793	7.38	39,014,806	7.38
Mr. P.P. Subasinghe	8,092,598	1.53	8,162,598	1.54
Employees Trust Fund Board	4,418,750	0.84	4,418,750	0.84
J.B. COCOSHELL Pvt Limited	2,384,677	0.45	1,981,308	0.37
MR. D.M. Rajapaksa / DR.MS. D.B.D. Rajapaksa	2,152,751	0.41	2,152,751	0.41
Mr. M.R. Weerasinghe (Deceased)	2,000,000	0.38	2,000,000	0.38
Mr.U. H. Palihakkara/Mrs. D.S. Palihakkara/Mr.K.D.H Palihakkara	1,352,046	0.26	1,352,046	0.26
MRS.Chandani Vishaka Ariyaratne/ MISS.B.A. Ariyaratne	1,333,333	0.25	1,333,333	0.25
Mr. M.D.N. Jayaratne	1,164,357	0.22	1,164,357	0.22
Mrs.Himali Sushama Jayaratne	1,164,356	0.22	1,164,356	0.22
Peoples Leasing and Finance PLC / S. Gobinath	1,000,000	0.19	-	0.00
Dr. Himali Rangika Jayasekera	818,988	0.15	818,988	0.15
Mr. Mohamed Faizer Hashim	762,239	0.14	762,239	0.14
Dr. W.M. Swarnamali Welagedara/MR. M.P.J. Senevirathne	749,999	0.14	749,999	0.14
Mr. Nagen Dayaranjan Kurukulasuriya	730,361	0.14	730,361	0.14
Mr. Godauda Pathiranage Kapilasena	722,499	0.14	722,499	0.00
Mr. Devapriya Senevirathna Epitawatta (Deceased)	666,666	0.13	666,666	0.13
Peoples Leasing & Finance PLC / S.P.S. Nishara	659,432	0.12	-	0.00
Mr. Abeysiri Hemapala Munasinghe	589,564	0.11	200,000	0.04
	492,332,822	93.16	492,336,375	93.03
Shares held by the balance shareholdings	36,124,723	6.84	36,121,170	6.87
Total Issued Shares	528,457,545	100.00	528,457,545	100.00
Public Shareholding	105,902,132	20.04	105,902,132	20.04
Total Number of Public Shareholders	4,013		3,631	

The Float- adjusted market capitalization as at 31st March 2026 is Rs.1,630,904,537.08
The Company is in compliance with option 5 of the CSE Listing Rules 7.13.1 (i) (a) which requires 20% minimum public holding percentage and 500 minimum public shareholders.

CORPORATE INFORMATION

Name of the Company
Asiri Surgical Hospital PLC

Registered Office
No. 21, Kirimandala Mawatha, Colombo 05, Sri Lanka. Telephone : 011 4524400
Email : info@asiri.lk
Web : www.asirihealth.com

Legal Form
A Quoted Public Company incorporated in Sri Lanka, under the Companies Act No. 17 of 1982 with limited liability.
The Company has re-registered under the Companies Act No. 07 of 2007. An undertaking approved by the Board of Investment of Sri Lanka (BOI) under the Board of Investment of Sri Lanka Law No. 4 of 1978.

Stock Exchange Listing
The Ordinary Shares of the Company are listed with the Colombo Stock Exchange.

Company Registration Number
PQ 208

Date of Incorporation
2nd March 2000

Directors
Mr. A.K. Pathirage - Chairman/Managing Director
Mr. H. K. Kaimal - Non- Independent Non- Executive
Mr. G. W.D.U.H. Gunawardena - Non - Independent Non - Executive
Mr. R. Selvaskandan - Independent Non-Executive
Mr. S. Shapira - Independent Non- Executive
Mr. M.I. Furkan - Independent Non - Executive
Mr. G.D.K.L.D. Silva - Independent Non- Executive

Auditors
Messrs Ernst & Young (Chartered Accountants) Rotunda Towers, No. 109, Galle Road, Colombo 03.

Secretaries
Messrs Softlogic Corporate Services (Pvt) Ltd. No. 14, De Fonseka Place, Colombo 05.

Stock Code
AMSL.N0000

Banks
Commercial Bank PLC
Hatton National Bank PLC
Nations Trust Bank PLC
Sampath Bank PLC
Cargills Bank Limited
National Development Bank PLC
DFCC Bank PLC

Subsidiary Companies
Asiri AOI Cancer Centre (Private) Limited
No. 21, Kirimandala Mawatha, Colombo 05, Sri Lanka

Audit Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal 0
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.De Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets quarterly

Remuneration Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.De Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets once a year

Nomination and Governance Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Related Party Transactions Review Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non-Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets quarterly